Secondary analysis of COMMANDS (350 evaluable patients with transfusion-dependent lower-risk MDS): luspatercept gave higher transfusion response than epoetin alfa across mutations (risk difference 0.25, 95% CI 0.15-0.35); responses were similar in RS-negative patients.
Secondary analysisn = 350
Komrokji et al. Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study